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Abstract 
Background: Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. 
Here, we study the efficacy and safety of albuvirtide (ABT), an HIV-1 fusion inhibitor with a half life of 11–12 days in 
human.
Methods: ABT was evaluated in a 7-week, open-label and randomized trial, combining with LPV/r. Twenty HIV-1-in-
fected adults were assigned to two dose groups, receiving ABT (160 or 320 mg) given weekly and LPV/r given twice 
daily.
Results: At week 7, the decline of HIV-1 RNA from baseline was 1.9 (1.3–2.3) log10 and 2.2 (1.6–2.7) log10 copies/ml, 
and suppression of HIV-1 RNA to below 50 copies/ml was achieved in 11.1 % (1/9) and 55.6 % (5/9) patients, for the 
160 and 320 mg dose group respectively.
Conclusion: A clear dose-efficacy correlation of ABT was demonstrated. ABT combining with LPV/r is a promising 
two-drug regimen to be tested in larger patient population.
© 2016 Zhang et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Current antiretroviral therapy (ART) requires strict life-
long adherence to daily drug taking. Long-acting ART 
agents, capable of being administered on a weekly or less 
frequent basis, have the potential to improve adherence 
to therapy and allow a more forgiving time window of 
drug administration [1].
Albuvirtide (ABT) is a chemically modified peptide 
derived from the N-terminal sequence of HIV-1 gp41, 
and contains a 3-maleimimidopropionic acid (MPA) 
group in its 13th lysine side chain [2]. Previous studies 
demonstrated that upon intravenous injection ABT could 
rapidly conjugate with serum albumin and dramatically 
extend the peptide in vivo half-life from 1.7 to 25.8 h in 
rats and from 10.9 to 102.4  h in monkeys [2]. A recent 
study using pseudoviruses showed potent inhibitory 
activity of ABT against a broad spectrum of HIV-1 
strains, including those commonly observed in China 
and some variants resistant to T20 [3]. A phase 1 single 
agent study in HIV-1 infected patients showed excellent 
safety profile of single and multiple dose of ABT, a half-
life of 11–12 days, and a clear dose related antiviral activ-
ity [4].
In this study in naive HIV-1 patients, a novel two-drug 
regimen combining ABT and lopinavir/ritonavir (LPV/r) 
was tested, their drug–drug interaction investigated, and 
short-term safety and efficacy profiles characterized.
Methods
Study population
Antiretroviral treatment-naïve HIV-1-infected patients 
aged 18–50 years were eligible for this study if they had 
HIV RNA levels between 5000 and 1,000,000 copies/
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ml, CD4 cell counts more than 350 cells/μl, body weight 
more than 40  kg and body mass index (BMI) between 
18.0 and 27.0 kg/m [2]. They had a normal level of albu-
min and no severe liver and kidney damage, and had not 
received any antiretroviral therapy for HIV and HBV or 
stopped antiretroviral therapy for more than 6  months. 
Exclusion criteria included acute HIV infection, severe 
opportunistic infections and tumors, severe diseases of 
digestive tract, hematology, metabolism, psychology and 
heredity, previous treatment of other HIV fusion inhibi-
tors, drug abuse, pregnancy, and breastfeeding. Female 
patients with child bearing potential and heterosexually 
active male patients were required to use effective contra-
ception during the study. The study was approved by the 
institutional ethics committee of Beijing You’an Hospital, 
and all potential subjects provided written informed con-
sent before undergoing procedures.
Study design
The study was a single-site, open-label, and randomized 
parallel study conducted in the Center for Infectious 
Diseases, Beijing You’an Hospital, Capital Medical Uni-
versity. Twenty antiretroviral treatment-naïve HIV-1 
infected patients were enrolled and randomized into 
two dose groups (10 in each group) to receive ABT by 
intravenous infusion at dose levels of 160 or 320 mg, and 
LPV/r (400/100 mg) twice daily. On Day 5–7, ABT was 
given daily for 3 days, then given weekly till Day 40; and 
LPV/r was given from Day 1 to 46. The subjects were fol-
lowed for a 47-day observation period. After the study all 
participants were treated with triple combination antivi-
ral therapy containing tenofovir, lamifudine and LPV/r.
The plasma HIV-1 RNA was measured using a 
branched-chain DNA method (bDNA, version 3.0, Bayer 
Healthcare LLC, Diagnostics Division, Tarrytown, NY) 
with a detection limit of 50 copies/ml. CD4 cell counts 
were measured using a FACS count system (FACS Cali-
bur, Becton Dickinson, USA).
Statistical analysis
This was a pilot study without power calculations or 
sample size estimation. Data were presented as the 
mean ± SD if not specified. The efficacy and safety analy-
ses were performed for the intent to treat (ITT) popula-
tion, defined as all subjects who were enrolled in the trial 
and received at least one dose of study medication. All 
statistical analyses were performed using SAS version 9.2.
Results
Twenty antiretroviral treatment-naïve HIV-1 infected 
patients (Table 1) were enrolled and randomized into two 
dose groups (10 in each group) to receive ABT (160 or 
320 mg) and LPV/r. There were no significant differences 
in age, body weight, HIV viral load and CD4 cell count 
at baseline between the two groups. Nineteen subjects 
completed the study with one withdrawal due to lost to 
follow-up. Two patients whose baseline HIV viral load 
did not meet the inclusion criteria and their viral load 
data were excluded from efficacy analysis. All 20 subjects 
were included in the pharmacokinetic and safety analysis.
From Day 14 till the end of the study, the viral load 
(plasma HIV-1 RNA) of all patients decreased >1.0 log10 
copies/ml. At the 47th day, the mean viral load decreased 
from baseline was 1.91 ± 0.36 log10 and 2.20 ± 0.33 log10 
copies/ml for the 160 and 320  mg groups, respectively 
(Fig. 1a). The percentage of subjects with viral load <50 
copies/ml was 11.1 % in the 160 mg group and 55.6 % in 
the 320 mg group (Fig. 1b). Pharmacokinetic/pharmaco-
dynamic (PK/PD) relationship analysis showed that the 
decrease of HIV viral load was positively correlated with 
AUC0-168h, Cmin and Ctrough of ABT. After treatment with 
ABT and LPV/r for 47  days, the mean absolute CD4+ 
cell count change relative to baseline was –5 cells/μl for 
the 160 mg group and 52 cells/μl for the 320 mg group 
respectively.
The pharmacokinetic profile of co-administration of 
ABT and LPV/r showed weak or no interaction. The 
results will be reported elsewhere. There were no serious 
adverse events during the 47 days of treatment. Eight cases 
of adverse events were observed in 7 subjects in 160 mg 
group and nine cases in 8 subjects in 320 mg group, but 
only six cases were related to investigational regimen in 
each group. All adverse events were mild, mainly triglyc-
erides level elevation, diarrhea, nausea and skin rash. No 
injection site reactions were found during the trial.
Discussion
In chronic management of HIV infection with ART, 
one of the most challenges is poor patient adherence to 
Table 1 Baseline characteristics of subjects
Data are presented as n or mean (range)
160 mg ABT + LPV/r 320 mg ABT + LPV/r
Randomized and treated10 10
Excluded 1 1
SS for safety analysis 10 10
ITT for efficacy analysis 9 9
Sex (male/female) 8/2 7/3
Race (Han/other) 9/1 10/0
Age (years) 31.9 (18~48) 37.4 (24~47)
Body weight (kg) 67.8 (53~88) 65.4 (53~76)
BMI (kg/m2) 22.8 (19~27) 22.8 (18~26)
Baseline HIV-1 RNA 
(log10 copies/ml)
4.27 (3.53~4.70) 4.27 (3.32~5.14)
Baseline CD4 (cell/μl) 517.0 (350~774) 566.6 (350~1070)
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treatment, which often results in treatment failure and 
emergence of drug resistance [5]. ABT is an experimen-
tal anti-HIV peptide targeting the HIV-1 envelop protein 
gp-41 at an area that’s different from that of T20. The 
13th residue of ABT contains a MPA modification that 
allows ABT to react with serum albumin. This extends its 
half-life to 11–12 days in human while retaining anti-HIV 
activity [3]. Although long-acting AIDS drugs are much 
sought after, how to administer such molecules with cur-
rent oral drugs remain to be studied.
In this phase 2 trial, we designed a two-drug regimen 
that includes a weekly given ABT and twice daily given 
LPV/r. It represents the first attempt to combine an 
approved, orally taken ART with a long-acting, inject-
able anti-HIV agent to treat HIV infected patients. 
For 47  days, the novel regimen was safe and exhibited 
potent anti-HIV activity. All treated patients, including 
one whose baseline viral load was  >5 log10 copies/ml, 
showed >1 log10 copies/ml reduction of viral load. Impor-
tantly, data of the 320 mg group showed a trend of supe-
rior anti-HIV activity to that of the 160 mg group. This 
demonstrates clear contribution of ABT to the plasma 
HIV RNA reduction in the two-drug regimen.
ABT is the first long-acting antiretroviral drug devel-
oping in China. With the limitation of no long-acting 
drugs combined with ABT, we also chose LPV/r for the 
ART regimen in the phase III clinical trial, a 48-week, 
randomized, controlled, open-label, multicenter study 
to investigate the safety and efficacy of ABT, which may 
have potential as next-generation HIV fusion inhibitors 
targeting gp41 for clinical use [6].
Conclusion
In summary, this 7-week study shows that ABT com-
bined with LPV/r is safe and effective. Compared with 
regimens of 3–4 drugs, the two-drug regimen could offer 
a simplified therapy with better safety and less drug–drug 
interaction. The long half-life of ABT potentially allows a 
3-day window for weekly administration and is more for-
giving in adherence than daily taken drugs.
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